MRK Related StreetInsider.com Reports
-
Cooperman's Omega Advisors Gets Into Gold and Silver ETFs (GLD) (GDX) (SLV) (more...)
-
Market Wrap: Loeb Eyes Sony Split; Wal-mart Gets Transparent; More Bullish on Tesla
-
Merck & Co., (MRK) guaranteed senior unsec. rating to A1 from Aa3 by Moody's
-
MSD (MRK) Awarded Large Portion of UNICEF HPV Teder
-
Merck (MRK) Says FDA Accepts BLA for Ragwee Pollen Tablet
-
Tesaro (TSRO) Faces Near-Term Risks to Key Drug - Report
-
Merck & Co. (MRK) Receives FDA Approval of LIPTRUZET as LDL Treatment in Certain Patients
-
StreetInsider.com Pre-Open Movers 5/1: (IQNT) (MSPD) (RATE) Higher; (HIMX) (MELA) (MRK) Lower (more...)
-
Merck (MRK) Tops Q1 EPS by 6c; Lowers FY13 EPS Outlook; Boosts Buyback
-
Merck (MRK) Adds $15B to Buyback Program
-
Trading Radar for 05/01: Facebook (FB), Clorox (CLX), MasterCard (MA), Chesapeake (CHK), Time Warner (TWX), Sands (LVS) Report
-
Pfizer (PFE) Q1 Results Might Signal Weakness at Merck (MRK)
-
Merck (MRK), Pfizer (PFE) Enter Ertugliflozin Development Agreement
-
Merck (MRK), Bristol-Myers Squib (BMY) Partner on Hepatitis C Combo
-
Streetinsider.com's Hot Lunchtime Reads 04/10: (JCP) (LIFE) (MRK) (MSFT) (BBY)
-
Mitigated Patent Risks, Strong Pipeline Bode Well for Merck (MRK) - Cramer
-
Merck (MRK) NDA for NOXAFIL Accepted by FDA
-
Jefferies Lifts PT on Pharmaceuticals Stocks (ABBV) (NVS) (SNY) (PFE)
-
Sales of Gilead (GILD) HCV Treatment Could Top $6B in U.S. Alone - Analyst
-
FDA Accepts Merck & Co (MRK) Grass Pollen Allergy Tablet BLA
-
Cantor Fitzgerald Slashes PT on Oncothyreon (ONTY) from $11 to $4
-
Zoetis (ZTS) Success Could Trigger Animal Healthcare Spin-Off Bonanza
-
Streetinsider.com's Hot Lunchtime Reads 03/12: (NOK) (JCP) (STM) (BHP) (MRK)
-
Analysts Weigh-In as Merck (MRK) IMPROVE-IT Set to Run to Completion
-
StreetInsider.com Pre-Open Movers 03/12: (GLUU) (ATEC) (YUM) Higher; (RSH) (DMND) (FCEL) Lower (more...)
-
DSMB Recommends that Merck (MRK) Continue IMPROVE-IT
-
Dow Jones Closes at New Record (Fun Factoids)
-
BofA/Merrill Lynch Upgrades Merck (MRK) to Buy
-
UPDATE: Wedbush Downgrades MAP Pharma (MAPP) to Neutral, Notes Other Potential M&A Targets
-
Merck & Co., Inc. (MRK) Declares $0.43 Quarterly Dividend; 4.1% Yield
-
Merck (MRK) Pays $215M to Settle Lawsuit
-
Cooperman's Omega Advisors Shows New Stakes in Facebook (FB), Crocs (CROX) and Freeport-McMoRan (FCX)
-
Merck & Co (MRK) Sees Q1 EPS Below the Street on Venezuelan Currency Devaluation
-
Notable Analyst Rating Changes 02/04: (BBRY) (BRO) (WU) Upgraded; (BUD) (WMT) (VOD) Downgraded
-
StreetInsider.com Pre-Open Movers 02/04: (APKT) (RMTI) (SONS) Higher; (HLF) (BUD) (NUS) Lower (more...)
-
Morgan Stanley Downgrades Merck (MRK) to Underweight
-
Leerink Swann Downgrades Merck (MRK) to Market Perform
-
StreetInsider.com Pre-Open Movers 02/01: (ADNC) (N) (RAD) Higher; (ECTE) (LTM) (OCZ) Lower (more...)
-
Merck (MRK) Ends '12 on High Note Despite SINGULAIR Weakness; '13 EPS Guidance Muted
-
Merck & Co., Inc. (MRK) Tops Q4 EPS by 2c; Guides In-Line
-
Trading Radar for 02/01: Exxon Mobil (XOM), Ingersoll-Rand (IR), Lear (LEA), Mattel (MAT), Newell (NWL) Report
-
Pfizer's Zoetis (ZTS) May be Largest IPO Since Facebook (FB)
-
Stocks Crossing 50-Day SMA 01/25: (CRUS) (MRK) (VRNG) Above; (CTRP) (S) (SWKS) Below
-
Merck (MRK) to Suspend TREDAPTIVE Availability
-
Notable ETF Movers of the Day 01/07: (XLV) Higher; (TAN) (XRT) Lower
-
Merck (MRK) Resubmits NDA for Ezetimibe, Atorvastatin Tabs
-
Technical Analyst Carter Worth Calls S&P 500 'Dead Money'
-
Meet Your 2013 Dogs of the Dow
-
Merck's (MRK) Tredaptive Miss May Benefit Amarin (AMRN) - Analyst
-
Merck (MRK) Says HPS2-THRIVE Missed Primary Endpoint
Back to MRK Stock Lookup
